Arda Therapeutics is pioneering the use of targeted cell depletion to treat chronic diseases. By identifying and selectively depleting pathogenic cells, Arda aims to develop therapies that offer greater efficacy, faster discovery timelines and reduced dosing frequency compared to traditional approaches. With a world-class team and a robust pipeline, Arda is poised to transform the landscape of chronic disease treatment.
“Arda is at the forefront of a paradigm shift in treating chronic diseases,” said Adam Freund, Ph.D., founder and CEO of Arda Therapeutics. “By focusing on the cells at the core of disease, we can develop therapies that are not only more effective, but also have the potential to fundamentally change patient outcomes. With drug approval rates declining and efficacy improvements stalling, Arda’s strategy to target cells—not pathways—offers a transformative shift in how chronic diseases are treated. With the support of our Series A investors, Arda is well positioned to progress our lead programs toward the clinic and expand our platform to tackle even more disease areas.”.
